List of Crinetics Pharmaceuticals patents

Patents where

Current Assignee

Name

Crinetics Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11834462 Somatostatin modulators and uses thereof	Patent 11834462 was granted and assigned to Crinetics Pharmaceuticals on December, 2023 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	11834462	December 5, 2023
‌ US Patent 11479540 Nonpeptide somatostatin type 5 receptor agonists and uses thereof	Patent 11479540 was granted and assigned to Crinetics Pharmaceuticals on October, 2022 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	11479540	October 25, 2022
‌ US Patent 11566015 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof		Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	11566015	January 31, 2023
‌ US Patent 11608335 Somatostatin modulators and uses thereof	Patent 11608335 was granted and assigned to Crinetics Pharmaceuticals on March, 2023 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	11608335	March 21, 2023
‌ US Patent 11072598 Somatostatin modulators and uses thereof	Patent 11072598 was granted and assigned to Crinetics Pharmaceuticals on July, 2021 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	11072598	July 27, 2021
‌ US Patent 11414397 Somatostatin modulators and uses thereof	Patent 11414397 was granted and assigned to Crinetics Pharmaceuticals on August, 2022 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	11414397	August 16, 2022
‌ US Patent 11186590 Somatostatin modulators and uses thereof	Patent 11186590 was granted and assigned to Crinetics Pharmaceuticals on November, 2021 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	11186590	November 30, 2021
‌ US Patent 11266641 Formulations of a somatostatin modulator	Patent 11266641 was granted and assigned to Crinetics Pharmaceuticals on March, 2022 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	11266641	March 8, 2022
‌ US Patent 10351547 Somatostatin modulators and uses thereof	Patent 10351547 was granted and assigned to Crinetics Pharmaceuticals on July, 2019 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	10351547	July 16, 2019
‌ US Patent 10696689 Somatostatin modulators and uses thereof	Patent 10696689 was granted and assigned to Crinetics Pharmaceuticals on June, 2020 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	10696689	June 30, 2020
‌ US Patent 10562884 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof	Patent 10562884 was granted and assigned to Crinetics Pharmaceuticals on February, 2020 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	10562884	February 18, 2020
‌ US Patent 9902703 Somatostatin modulators and uses thereof	Patent 9902703 was granted and assigned to Crinetics Pharmaceuticals on February, 2018 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	9902703	February 27, 2018
‌ US Patent 10875839 Somatostatin modulators and uses thereof	Patent 10875839 was granted and assigned to Crinetics Pharmaceuticals on December, 2020 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	10875839	December 29, 2020
‌ US Patent 10597377 Somatostatin modulators and uses thereof	Patent 10597377 was granted and assigned to Crinetics Pharmaceuticals on March, 2020 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	10597377	March 24, 2020
‌ US Patent 10981894 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof	Patent 10981894 was granted and assigned to Crinetics Pharmaceuticals on April, 2021 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	10981894	April 20, 2021
‌ US Patent 11028068 Somatostatin modulators and uses thereof	Patent 11028068 was granted and assigned to Crinetics Pharmaceuticals on June, 2021 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	11028068	June 8, 2021
‌ US Patent 10464918 Process of making somatostatin modulators	Patent 10464918 was granted and assigned to Crinetics Pharmaceuticals on November, 2019 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	10464918	November 5, 2019
‌ US Patent 10766877 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof		Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	10766877	September 8, 2020
‌ US Patent 10889561 Process of making somatostatin modulators	Patent 10889561 was granted and assigned to Crinetics Pharmaceuticals on January, 2021 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	10889561	January 12, 2021
‌ US Patent 10604507 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof		Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	10604507	March 31, 2020
‌ US Patent 9896432 Somatostatin modulators and uses thereof	Patent 9896432 was granted and assigned to Crinetics Pharmaceuticals on February, 2018 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	9896432	February 20, 2018
‌ US Patent 9957267 Somatostatin modulators and uses thereof	Patent 9957267 was granted and assigned to Crinetics Pharmaceuticals on May, 2018 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	9957267	May 1, 2018
‌ US Patent 11773076 Crystalline forms of a somatostatin modulator	Patent 11773076 was granted and assigned to Crinetics Pharmaceuticals on October, 2023 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	11773076	October 3, 2023
‌ US Patent 12134610 Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof	Patent 12134610 was granted and assigned to Crinetics Pharmaceuticals on November, 2024 by the United States Patent and Trademark Office.	Crinetics Pharmaceuticals	Crinetics Pharmaceuticals	United States Patent and Trademark Office	12134610	November 5, 2024

24 results

0 selected

24 results

0 selected